Otis Brawley: CMS Got it Right in Lung Cancer Screening Coverage Decision

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

This week the Centers for Medicare & Medicaid Services issued a proposed rule stating that the scientific evidence was sufficient to support reimbursement for counseling on the risks and benefits of lung cancer screening as well as lung cancer screening with low dose computed tomography in high risk individuals and once per year. CMS will pay for such services when provided to beneficiaries at high risk for lung cancer and when provided by physicians and centers with specific qualifications.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Otis W. Brawley, MD, MACP
Chief scientific and medical officer, American Cancer Society
Table of Contents

YOU MAY BE INTERESTED IN

As NCI and NIH funding is being deliberated in Congress, this year’s 2025 AACR Cancer Progress Report had an unequivocal message: With 20 new anticancer therapeutics, new uses for eight previously approved anticancer therapeutics, two new early detection tools, and several AI-powered diagnostics approved over the span of just one year, cancer research funding yields a good return on investment. 
Otis W. Brawley, MD, MACP
Chief scientific and medical officer, American Cancer Society

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login